Premium
Statin and NSAID use and prostate cancer risk
Author(s) -
Coogan Patricia F.,
Kelly Judith Parsells,
Strom Brian L.,
Rosenberg Lynn
Publication year - 2010
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.1970
Subject(s) - medicine , statin , odds ratio , prostate cancer , logistic regression , confidence interval , cancer , pharmacoepidemiology , case control study , odds , oncology , medical prescription , pharmacology
Purpose Some studies have reported reduced risks of advanced, but not early, prostate cancer among statin users, and one study found a reduced risk only among statin users who had also used non‐steroidal anti‐inflammatory drugs (NSAIDs). We have previously reported no association between statin use and prostate cancer in our hospital‐based Case Control Surveillance Study. The purpose of the present analyses was to update the findings by cancer stage and to evaluate the joint use of statins and NSAIDs. Methods Cases were 1367 men with prostate cancer and controls were 2007 men with diagnoses unrelated to statin or NSAID use. We used multivariable logistic regression analyses to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for statin use compared with no use, and joint use of statin and NSAIDs compared with use of neither. Results The odds ratio among regular statin users was 1.1 (95%CI 0.9–1.5), and odds ratios were similar among early and late stage cancers. The odds ratio among joint statin and NSAID users was 1.1 (95%CI 0.7–1.6). Conclusion The present results do not support a protective effect of statin use, or statin and NSAID use, on the risk of advanced prostate cancer. Copyright © 2010 John Wiley & Sons, Ltd.